Patients with non-small cell lung cancer (NSCLC) often harbor driver mutations in multiple oncogenes, including EGFR, RAS, ALK, ROS1, BRAF, HER2, RET, etc., [1]. This evidence concerns the gene ALK and non-small cell lung carcinoma.